[go: up one dir, main page]

WO1996001430A3 - Criblage d'inhibiteurs de nuc - Google Patents

Criblage d'inhibiteurs de nuc Download PDF

Info

Publication number
WO1996001430A3
WO1996001430A3 PCT/US1995/008328 US9508328W WO9601430A3 WO 1996001430 A3 WO1996001430 A3 WO 1996001430A3 US 9508328 W US9508328 W US 9508328W WO 9601430 A3 WO9601430 A3 WO 9601430A3
Authority
WO
WIPO (PCT)
Prior art keywords
nuc
protein
screening
agents
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1995/008328
Other languages
English (en)
Other versions
WO1996001430A2 (fr
Inventor
Ranjan Mukherjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Priority to AU29571/95A priority Critical patent/AU2957195A/en
Priority to EP95925440A priority patent/EP0769146A2/fr
Priority to JP8503950A priority patent/JPH10502454A/ja
Publication of WO1996001430A2 publication Critical patent/WO1996001430A2/fr
Publication of WO1996001430A3 publication Critical patent/WO1996001430A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)

Abstract

L'invention concerne des méthodes de criblage d'agents utilisés pour le traitement de maladies et d'états pathologiques affectés par le niveau d'activité de la protéine NUC. Ces agents réduisent ou atténuent la répression de l'activité d'activation transcriptionnelle de la protéine PPARα et de la protéine TR par la protéine NUC. Ces agents nouveaux ou uniques, sélectionnés, peuvent être utilisés pour traiter l'hyperlipidémie, l'hypercholestérolémie et l'hyperlipoprotéinémie.
PCT/US1995/008328 1994-07-01 1995-06-29 Criblage d'inhibiteurs de nuc Ceased WO1996001430A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU29571/95A AU2957195A (en) 1994-07-01 1995-06-29 Screening for nuc inhibitors
EP95925440A EP0769146A2 (fr) 1994-07-01 1995-06-29 Criblage d'inhibiteurs de nuc
JP8503950A JPH10502454A (ja) 1994-07-01 1995-06-29 Ｎｕｃ阻害剤のスクリーニング

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27063594A 1994-07-01 1994-07-01
US08/270,635 1994-07-01

Publications (2)

Publication Number Publication Date
WO1996001430A2 WO1996001430A2 (fr) 1996-01-18
WO1996001430A3 true WO1996001430A3 (fr) 1996-10-10

Family

ID=23032149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008328 Ceased WO1996001430A2 (fr) 1994-07-01 1995-06-29 Criblage d'inhibiteurs de nuc

Country Status (5)

Country Link
EP (1) EP0769146A2 (fr)
JP (1) JPH10502454A (fr)
AU (1) AU2957195A (fr)
CA (1) CA2193685A1 (fr)
WO (1) WO1996001430A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
US7635708B2 (en) 1996-12-11 2009-12-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
EP1083891B1 (fr) 1998-06-02 2003-03-12 Arthromics PLC Composes capables d'interaction avec le recepteur d'hormone thyroidienne pour le traitement des maladies fibrosantes
WO2006033891A2 (fr) 2004-09-16 2006-03-30 Merck & Co., Inc. Composes pour traitement de la dyslipidemie et autres troubles lipidiques

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011974A2 (fr) * 1993-10-22 1995-05-04 Ligand Pharmaceuticals, Inc. Recepteur active de l'agent de proliferation du peroxisome humain
WO1995018533A1 (fr) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Procedes et composes exerçant un effet sur la differentiation des adipocytes et sur l'obesite
WO1996001317A2 (fr) * 1994-07-01 1996-01-18 The Salk Institute For Biological Studies Recepteurs actives par les proliferateurs de peroxysomes mammaliens et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011974A2 (fr) * 1993-10-22 1995-05-04 Ligand Pharmaceuticals, Inc. Recepteur active de l'agent de proliferation du peroxisome humain
WO1995018533A1 (fr) * 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Procedes et composes exerçant un effet sur la differentiation des adipocytes et sur l'obesite
WO1996001317A2 (fr) * 1994-07-01 1996-01-18 The Salk Institute For Biological Studies Recepteurs actives par les proliferateurs de peroxysomes mammaliens et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. SCHMIDT ET AL.: "Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids.", MOLECULAR ENDOCRINOLOGY, vol. 6, no. 10, 1992, WASHINGTON DC USA, pages 749 - 784, XP000579262 *
F. CHEN ET AL.: "Identification of two mPPAR related receptors and evidence for the existence of five subfamily members", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 196, no. 2, 1993, NEW YORK NY USA, pages 671 - 677, XP000577084 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635708B2 (en) 1996-12-11 2009-12-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor

Also Published As

Publication number Publication date
AU2957195A (en) 1996-01-25
EP0769146A2 (fr) 1997-04-23
CA2193685A1 (fr) 1996-01-18
JPH10502454A (ja) 1998-03-03
WO1996001430A2 (fr) 1996-01-18

Similar Documents

Publication Publication Date Title
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
FI964339L (fi) Glukaanien entsyymikäsittely
GB9323165D0 (en) Compounds
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
EE9900036A (et) Uued ühendid ja kompositsioonid trüptaasi aktiivsusega seotud haiguste raviks
WO2001021647A3 (fr) Procedes de criblage de composes qui modulent l'interaction de la lsr-leptine et utilisations de ces composes dans la prevention et le traitement des maladies liees a l'obesite
DE69830069D1 (de) Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
DE69635708D1 (de) Tetrandrin zur behandlung von augenentzündungen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
MA25404A1 (fr) Methode pour le traitement des desordres neurologiques ou neuropsychiatriques.
WO1997003188A3 (fr) Utilisation de mp52 ou de mp121 pour la therapie et la prophylaxie de maladies du systeme nerveux
BG109411A (en) METHOD FOR OBTAINING HIV-PROTEZATE INHIBITORS
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
WO1996001430A3 (fr) Criblage d'inhibiteurs de nuc
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CN CZ ES FI GE HU IS JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL PT RO RU SD SG SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CN CZ ES FI GE HU IS JP KE KG KP KR KZ LK LT LV MD MG MN MW NO NZ PL PT RO RU SD SG SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2193685

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995925440

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995925440

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995925440

Country of ref document: EP